Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Martin

Showing results (1-10 of 216) with videos related to

Pageof 22
Sort By:
Trends in Pharmacological Sciences|December 5, 2003
Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?Roland Martin
Clinical Immunology (Orlando, Fla.)|January 31, 2012
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosisRoland Martin
Nature|March 19, 2010
Multiple sclerosis: closing in on an oral treatmentRoland Martin
The Lancet. Neurology|August 16, 2008
Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosisRoland Martin
Nature Medicine|November 8, 2008
HLA class I: friend and foe of multiple sclerosisRoland Martin
Nature Immunology|October 17, 2018
Targeting fibrin in neurodegenerationRoland Martin
Brain : a Journal of Neurology|May 3, 2007
Is haematopoietic stem cell transplantation a treatment option for severe MS or not?Roland Martin
The Lancet. Neurology|April 17, 2018
Understanding risk of PML through multiple sclerosisRoland Martin
Neuro-Degenerative Diseases|December 14, 2007
Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosisRoland Martin
Seminars in Neurology|April 27, 2016
Immunology of Multiple SclerosisMireia Sospedra, Roland Martin
Pageof 22

Showing results (1-10 of 216) with videos related to

Sort By:
Pageof 22
Trends in Pharmacological Sciences|December 5, 2003
Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?Roland Martin
Clinical Immunology (Orlando, Fla.)|January 31, 2012
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosisRoland Martin
Nature|March 19, 2010
Multiple sclerosis: closing in on an oral treatmentRoland Martin
The Lancet. Neurology|August 16, 2008
Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosisRoland Martin
Nature Medicine|November 8, 2008
HLA class I: friend and foe of multiple sclerosisRoland Martin
Nature Immunology|October 17, 2018
Targeting fibrin in neurodegenerationRoland Martin
Brain : a Journal of Neurology|May 3, 2007
Is haematopoietic stem cell transplantation a treatment option for severe MS or not?Roland Martin
The Lancet. Neurology|April 17, 2018
Understanding risk of PML through multiple sclerosisRoland Martin
Neuro-Degenerative Diseases|December 14, 2007
Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosisRoland Martin
Seminars in Neurology|April 27, 2016
Immunology of Multiple SclerosisMireia Sospedra, Roland Martin
Pageof 22